CooperVision Misses Revenue, Yet Stock Plunges

The Cooper Companies reported fiscal 2026 Q3 earnings on September 9, 2026. While non-GAAP EPS of $1.15 beat expectations by $0.03, revenue of $1.07 billion missed consensus by $30 million. The company raised its full-year 2026 revenue and EPS guidance, reflecting optimism in underlying demand despite near-term inventory adjustments in the U.S. channel.

Revenue

The Cooper Companies reported a total revenue increase of 0.6% to $1.07 billion in Q3 2026, up from $1.06 billion in the prior year period. CooperVision net sales totaled $717 million, driven by $363.80 million in Toric and multifocal products and $353.20 million in Sphere and other categories. CooperSurgical contributed $349.20 million, while Office and Surgical segments added $208 million. Fertility revenue stood at $141.20 million, with Corporate revenues recorded at $0, bringing total net sales to the reported $1.07 billion.

Earnings/Net Income

The Cooper Companies's EPS rose 357.1% to $2.24 in 2026 Q3 from $0.49 in 2025 Q3, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $432.80 million in 2026 Q3, marking 340.3% growth from $98.30 million in 2025 Q3. This substantial margin expansion indicates highly effective cost management and operational leverage during the quarter.

Price Action

The stock price of The Cooper Companies has dropped 5.35% during the latest trading day, has tumbled 8.37% during the most recent full trading week, and has tumbled 14.48% month-to-date.

Post-Earnings Price Action Review

The Cooper Companies experienced significant downward pressure following the earnings release, with the stock declining 5.35% on the trading day and sustaining a 14.48% loss month-to-date. This negative sentiment appears driven by the revenue miss relative to consensus estimates, which fell $30 million short, despite the strong beat on non-GAAP EPS. The broader weekly decline of 8.37% suggests that investors are prioritizing top-line concerns over bottom-line improvements, reflecting caution regarding the guidance for flat organic growth in the CooperVision segment for Q4.

CEO Commentary

CEO Al White highlighted that while underlying U.S. demand remains healthy with mid-single-digit consumption growth, CooperVision’s results were negatively impacted by proactive U.S. channel inventory reductions, which will persist into Q4. The company is intensifying focus on profitable organic growth through expanded sales coverage, marketing programs, and AI-driven analytics, particularly in the Americas and Asia-Pac. Strategic priorities include accelerating product launches like MyDay MiSight and enhancing commercial execution to convert contract wins into revenue. The leadership outlook is cautiously optimistic, emphasizing that long-term growth drivers are intact and that recent investments in infrastructure and personnel position the company for stronger performance in fiscal 2027, despite near-term margin pressures from increased spending.

Guidance

For Q4, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing 0%-2% organic growth. CooperVision revenue is guided between $692 million and $706 million, indicating flat to -2% organic growth, while CooperSurgical revenue is expected to range from $364 million to $374 million, reflecting 4%-6% organic growth. Non-GAAP EPS is projected at $1.05 to $1.09, with an effective tax rate of approximately 16%. Interest expense is estimated at roughly $25 million. Free cash flow is expected to be around $170 million, excluding litigation payments. The company anticipates FX headwinds and lower tariff refunds will pressure margins in Q4 compared to Q3, with no specific fiscal 2027 guidance provided other than noting a potential tax rate increase to roughly 17.5% due to GILTI changes.

Additional News

Strategic discussions regarding potential mergers and acquisitions have intensified within the ophthalmic device sector, positioning Cooper Companies as a key player in consolidation trends. Leadership stability remains a focal point, with no recent C-level changes reported, ensuring continuity in the current growth strategy. Meanwhile, the company reaffirmed its commitment to returning capital to shareholders, maintaining its long-term free cash flow objective exceeding $2.2 billion for fiscal years 2026 through 2028. Industry analysts have also highlighted the firm's robust cash conversion capabilities, suggesting that its strong balance sheet provides strategic optionality for future investments. This financial flexibility is viewed as a critical advantage in navigating near-term market volatility and capitalizing on emerging opportunities in digital health and advanced vision care technologies, reinforcing investor confidence in the company's operational resilience.